Abstract:BackgroundGlobal DNA methylation alterations are hallmarks of cancer. The tumor-suppressive TET enzymes, which are involved in DNA demethylation, are decreased in prostate cancer (PCa); in particular, TET2 is specifically targeted by androgen-dependent mechanisms of repression in PCa and may play a central role in carcinogenesis. Thus, the identification of key genes targeted by TET2 dysregulation may provide further insight into cancer biology.ResultsUsing a CRISPR/Cas9-derived TET2-knockout prostate cell line, and through whole-transcriptome and whole-methylome sequencing, we identified seven candidate genes—ASB2, ETNK2, MEIS2, NRG1, NTN1, NUDT10, and SRPX—exhibiting reduced expression and increased promoter methylation, a pattern characteristic of tumor suppressors. Decreased expression of these genes significantly discriminates between recurrent and non-recurrent prostate tumors from the Cancer Genome Atlas (TCGA) cohort (n = 423), and ASB2, NUDT10, and SRPX were significantly correlated with lower recurrence-free survival in patients by Kaplan-Meier analysis. ASB2, MEIS2, and SRPX also showed significantly lower expression in high-risk Gleason score 8 tumors as compared to low or intermediate risk tumors, suggesting that these genes may be particularly useful as indicators of PCa progression. Furthermore, methylation array probes in the TCGA dataset, which were proximal to the highly conserved, differentially methylated sites identified in our TET2-knockout cells, were able to significantly distinguish between matched prostate tumor and normal prostate tissues (n = 50 pairs). Except ASB2, all genes exhibited significantly increased methylation at these probes, and methylation status of at least one probe for each of these genes showed association with measures of PCa progression such as recurrence, stage, or Gleason score. Since ASB2 did not have any probes within the TET2-knockout differentially methylated region, we validated ASB2 methylation in an independent series of matched tumor-normal samples (n = 19) by methylation-specific qPCR, which revealed concordant and significant increases in promoter methylation within the TET2-knockout site.ConclusionsOur study identifies seven genes governed by TET2 loss in PCa which exhibit an association between their methylation and expression status and measures of PCa progression. As differential methylation profiles and TET2 expression are associated with advanced PCa, further investigation of these specialized TET2 targets may provide important insights into patterns of carcinogenic gene dysregulation.

TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression

Expression of 5-methylcytosine regulators is highly associated with the clinical phenotypes of prostate cancer and <i>DNMTs</i> expression predicts biochemical recurrence

Hypermethylation-mediated Transcriptional Repression of TMPRSS2 in Androgen Receptor-Negative Prostate Cancer Cells

Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases.

Comprehensive Analysis of M5c Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.

Demethylation of EHMT1/GLP protein reprograms its transcriptional activity and promotes prostate cancer progression

Androgen Receptor is Negatively Correlated with the Methylation-Mediated Transcriptional Repression of Mir-375 in Human Prostate Cancer Cells.

Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ER alpha-positive breast cancer cells

Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype

Ten-eleven translocation proteins (TETs): tumor suppressors or tumor enhancers?

DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs

TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence.

Abstract 5878: ZNF397 loss triggers TET2-driven epigenetic rewiring, lineage plasticity, and AR-targeted therapy resistance

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Epigenetic modification‐dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells

Attenuation of TGFBR2 Expression and Tumour Progression in Prostate Cancer Involve Diverse Hypoxia-Regulated Pathways.

TWIST2: A New Candidate Tumor Suppressor in Prostate Cancer

Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer

Tgf-Beta Regulates Dna Methyltransferase Expression In Prostate Cancer, Correlates With Aggressive Capabilities, And Predicts Disease Recurrence